Rheolytic thrombectomy in acute myocardial infarction: the Florence experience and objectives of the multicenter...

Area of Science:

• Cardiology
• Interventional Cardiology
• Biomedical Engineering

Background:

• Percutaneous coronary intervention (PCI) is a standard treatment for acute myocardial infarction (MI).
• The role of rheolytic thrombectomy prior to stenting in acute MI requires further investigation.
• Optimizing reperfusion and minimizing infarct size are critical goals in acute MI management.

Purpose of the Study:

• To assess the efficacy of rheolytic thrombectomy before direct infarct artery stent implantation in acute MI patients.
• To confirm the findings of the Florence-AngioJet trial in a larger, multi-center international study (JETSTENT trial).
• To evaluate if this combined approach improves myocardial salvage and reduces adverse cardiac remodeling.

Main Methods:

• The Florence-AngioJet trial randomized 100 patients with first acute MI.
• The JETSTENT trial is a multi-center international randomized trial enrolling 500 patients with acute MI, including those with prior MI and cardiogenic shock.
• Both trials compared rheolytic thrombectomy with AngioJet followed by stenting versus direct stenting alone, assessing early ST-segment resolution, corrected Thrombolysis In Myocardial Infarction (TIMI) frame count, and infarct size.

Main Results:

• In the Florence-AngioJet trial, patients receiving thrombectomy before stenting showed significantly higher early ST-segment elevation resolution (90% vs. 72%, p=0.022).
• Thrombectomy group had significantly lower corrected TIMI frame counts (18.2 vs. 22.5, p=0.032) and smaller infarct sizes (13.0% vs. 21.2%, p=0.010).
• The JETSTENT trial aims to confirm these positive results in a broader patient population.

Conclusions:

• Rheolytic thrombectomy prior to direct stenting is an effective strategy for improving reperfusion and reducing infarct size in acute MI.
• The JETSTENT trial is designed to provide further evidence supporting this approach in a diverse acute MI population.
• This strategy holds promise for improving long-term cardiac function and reducing heart failure incidence post-MI.